{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:16:45Z","timestamp":1787847405794,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shattuck Labs, Inc."},{"name":"Shattuck Labs Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,6,20]]},"DOI":"10.1038\/s41416-026-03430-0","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:04:11Z","timestamp":1775664251000},"page":"1754-1763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-9224","authenticated-orcid":false,"given":"Yvette","family":"Drew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Martinez Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7194","authenticated-orcid":false,"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-4236","authenticated-orcid":false,"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Gaba Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon C.","family":"Jayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-1326","authenticated-orcid":false,"given":"Rebecca S.","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8840-7934","authenticated-orcid":false,"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-5035","authenticated-orcid":false,"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Yiannakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Pilar","family":"Barretina-Ginesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f3nimo","family":"Mart\u00ednez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayalakshmi","family":"Miriyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9128-7128","authenticated-orcid":false,"given":"Elisa","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9194-6348","authenticated-orcid":false,"given":"Lini","family":"Pandite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"3430_CR1","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garcia Y, Banerjee S, Lorusso D, et al. Mirvetuximab Soravtansine in FRalpha-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023;389:2162\u201374.","journal-title":"N Engl J Med."},{"key":"3430_CR2","doi-asserted-by":"crossref","unstructured":"Gupta V, Yull F, Khabele D. Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy. Cancers (Basel). 2018;10:366.","DOI":"10.3390\/cancers10100366"},{"key":"3430_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2346359","volume":"13","author":"M Witt","year":"2024","unstructured":"Witt M, Oliveira-Ferrer L, Koch-Nolte F, Menzel S, Hell L, Sturmheit T, et al. Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction. Oncoimmunology. 2024;13:2346359.","journal-title":"Oncoimmunology."},{"key":"3430_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-023-00322-4","volume":"9","author":"E Yakubovich","year":"2023","unstructured":"Yakubovich E, Cook DP, Rodriguez GM, Vanderhyden BC. Mesenchymal ovarian cancer cells promote CD8(+) T cell exhaustion through the LGALS3-LAG3 axis. NPJ Syst Biol Appl. 2023;9:61.","journal-title":"NPJ Syst Biol Appl."},{"key":"3430_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2016.08.325","volume":"143","author":"RM Brightwell","year":"2016","unstructured":"Brightwell RM, Grzankowski KS, Lele S, Eng K, Arshad M, Chen H, et al. The CD47 \u201cdon\u2019t eat me signal\u201d is highly expressed in human ovarian cancer. Gynecol Oncol. 2016;143:393\u20137.","journal-title":"Gynecol Oncol."},{"key":"3430_CR6","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/ijms16023391","volume":"16","author":"H Wang","year":"2015","unstructured":"Wang H, Tan M, Zhang S, Li X, Gao J, Zhang D, et al. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol Sci. 2015;16:3391\u2013404.","journal-title":"Int J Mol Sci."},{"key":"3430_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24:225\u201332.","journal-title":"Curr Opin Immunol."},{"key":"3430_CR8","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 2012;109:6662\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"key":"3430_CR9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21:1209\u201315.","journal-title":"Nat Med."},{"key":"3430_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1084\/jem.20021542","volume":"198","author":"L Delamarre","year":"2003","unstructured":"Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med. 2003;198:111\u201322.","journal-title":"J Exp Med."},{"key":"3430_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.4049\/jimmunol.165.2.795","volume":"165","author":"PJ O\u2019Connell","year":"2000","unstructured":"O\u2019Connell PJ, Morelli AE, Logar AJ, Thomson AW. Phenotypic and functional characterization of mouse hepatic CD8 alpha+ lymphoid-related dendritic cells. J Immunol. 2000;165:795\u2013803.","journal-title":"J Immunol."},{"key":"3430_CR12","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.4049\/jimmunol.172.8.4826","volume":"172","author":"T Yasumi","year":"2004","unstructured":"Yasumi T, Katamura K, Yoshioka T, Meguro TA, Nishikomori R, Heike T, et al. Differential requirement for the CD40-CD154 costimulatory pathway during Th cell priming by CD8 alpha+ and CD8 alpha-murine dendritic cell subsets. J Immunol. 2004;172:4826\u201333.","journal-title":"J Immunol."},{"key":"3430_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/2326-6066.CIR-19-0493","volume":"8","author":"S de Silva","year":"2020","unstructured":"de Silva S, Fromm G, Shuptrine CW, Johannes K, Patel A, Yoo KJ, et al. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. Cancer Immunol Res. 2020;8:230\u201345.","journal-title":"Cancer Immunol Res."},{"key":"3430_CR14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/JCO.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol. 2019;37:946\u201353.","journal-title":"J Clin Oncol."},{"key":"3430_CR15","doi-asserted-by":"crossref","unstructured":"Lakhani NJ, Stewart D, Richardson DL, Dockery LE, Van Le L, Call J, et al. First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. J Immunother Cancer. 2025;13:e010565.","DOI":"10.1136\/jitc-2024-010565"},{"key":"3430_CR16","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22:1034\u201346.","journal-title":"Lancet Oncol."},{"key":"3430_CR17","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302\u20138.","journal-title":"J Clin Oncol."},{"key":"3430_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.molmed.2008.02.002","volume":"14","author":"L Apetoh","year":"2008","unstructured":"Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med. 2008;14:141\u201351.","journal-title":"Trends Mol Med."},{"key":"3430_CR19","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u2013e52.","journal-title":"Lancet Oncol."},{"key":"3430_CR20","unstructured":"Mirvetuximab FDA Label. https:\/\/www.accessdatafdagov\/drugsatfda_docs\/label\/2022\/761310s000lblpdf."},{"key":"3430_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH. CD40 Agonist Antibodies in Cancer Immunotherapy. Annu Rev Med. 2020;71:47\u201358.","journal-title":"Annu Rev Med."},{"key":"3430_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12957-020-02101-5","volume":"19","author":"L Ye","year":"2021","unstructured":"Ye L, Cai L, Fu Y, Zhuang D, Hu X, Jie Y. The prevalence, risk factors, and prognostic value of venous thromboembolism in ovarian cancer patients receiving chemotherapy: a systematic review and meta-analysis. World J Surg Oncol. 2021;19:12.","journal-title":"World J Surg Oncol."},{"key":"3430_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ygyno.2024.02.011","volume":"185","author":"S Penfound","year":"2024","unstructured":"Penfound S, Lukey A, Hodgson J, Hopman WM, Hanley GE, Othman M. Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database. Gynecol Oncol. 2024;185:116\u201320.","journal-title":"Gynecol Oncol."},{"key":"3430_CR24","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023;41:2436\u201345.","journal-title":"J Clin Oncol."},{"key":"3430_CR25","doi-asserted-by":"crossref","unstructured":"Moore KOA, Colombo N, Oaknin A, Scambia G, Lorusso D, Farias-Eisner R, et al. FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Annals of Oncology, European Society of Medical Oncology 2019.","DOI":"10.1093\/annonc\/mdz250"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03430-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03430-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03430-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:01:56Z","timestamp":1780362116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03430-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,20]]}},"alternative-id":["3430"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03430-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YD received institutional research funding from Shattuck Labs for this study. She also reports institutional research funding from GlaxoSmithKline and AstraZeneca, and honoraria for educational meetings or serving in an advisory role for Merck, AbbVie, GlaxoSmithKline, and AstraZeneca. LG received institutional research funding from Shattuck Labs for this study. She also reports institutional grants from Alkermes, Ascendis, AstraZeneca, Bayer, CanariaBio Inc, Corcept Therapeutics, Daiichi Sankyo Inc, Eisai, Espersas, Fortrea Inc, GmbH, GOG Foundation, GSK, ImmunoGen, IMV, K-Group Beta Inc, Karyopharm, Merck, Mersana Therapeutics, Novocure, OncoQuest Pharmaceuticals, Paraxel International, Pfizer, Pri-Wex Pharma Inc, Repare Therapeutics, Roche, Seagen Inc, Sichuan Kelun Biotech Biopharma, Parexel, Sutro Bio Pharma, and Tesar. She reports honoraria for Advisory Board Meetings from CabaruaBio Inc., Corcept Therapeutics, Eisai, GSK, ImmunoGen, Karyopharm, Kora Health Care, Merck, Novocure and Repare Therapeutics. AMB received institutional research funding from Shattuck Labs for this study. He also reports honoraria for consulting from GSK, AstraZeneca and Novartis. AO (Ana Oaknin) received institutional research funding from Shattuck Labs for this study. She also reports consulting fees for serving in an advisory role for AbbVie Inc., Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Da\u00efichi Sankyo, Debiopharm International, Eisai, Exelixis, F. Hoffmann-La Roche, Genmab, GSK, ImmunoGen, Itheos, MSD, Mersana Therapeutics, Myriad Genetics, Novocure, OncoXerna Therapeutics, Inc., PharmaMar, Regeneron, ShattuckLabs, Seagen\/Pfizer, Stemline Therapeutics, Sutro Biopharma, TORL Therapeutics, Zentalis and Zymeworks. She also received honoraria from NSGO, Peerview, Peervoice, Medscape, Asociaci\u00f3n Colombiada de Ginecol\u00f3gos Onc\u00f3logos, ESO. VM received institutional research funding from Shattuck Labs for this study. He also reports institutional research funding from AbbVie, Achilles, Adaptimmune, Adc Therapeutics, Ascendis Pharma, AstraZeneca, Bayer, Beigene, Bicycle Tx, Bioinvent, Biomea Fusion, Biontech, Bms, Boehringer, C4 Therapeutics, Calico Life Sciences Llc, Celgene, Constellation, Crescendo Biologics, Cullinan, Daiichi Sankyo, Debiopharm, Dragonfly, Enliven Therapeutics, Epizyme, Exelixis, Famewave, F-Star Beta Limited, Genentech, Genmab, Gilead, Grey Wolf Therapeutics, GSK, Hexal Ag & Sandoz, Hifibio, Hookipa Biotech, Hutchmed, Igm Biosciences, Imcheck Therapeutics, Immunocore, Immutep, Incyte Iomx Therapeutics, Iovance, Italfarmaco, Iteos, Janssen, Light Chain Bioscience, Lilly, Loxo Oncology, Merck, Merus, Miltenyi Biomedicine, Monta Biosciences, Msd, Mythic Therapeutics, Ningbo Newbay, Novartis, Oxford Biotherapeutics, Pfizer, Pharmamar, Pmv Pharma, Prelude Therapeutics Inc, Pyxis Oncology, Regeneron, Relay Terapeutics, Repare Therapeutics, Revolution, Roche, Schr\u00f6dinger, Scorpion Therapeutics, Seagen, Synthorx, Takeda, Tango Therapeutics, Tesaro, Totus Medicines, Turning Point Therapeutics, Vividion Therapeutics. He has consulted and received fees from AbbVie, Roche, Bayer, BMS, Janssen, Syneos, Affimed, Astra Zeneca, Merck, Ellipses Pharma. LGG received institutional research funding from Shattuck Labs for this study. She also received consulting fees from AbbVie, AstraZeneca, Clovis Oncology, Daiichi Sankyo, GSK, MSD, Pharma&, and PharmaMar. GCJ received institutional research funding from Shattuck Labs for this study. He also reports honoraria for educational events from GSK, PHARMA, AstraZeneca, and Novartis, and institutional funding for investigator led research from AstraZeneca. RK received institutional research funding from Shattuck Labs for this study. She also reports honoraria for educational meetings or for serving as an advisor for Abbvie, AstraZeneca, Duke Street Bio, Eisai, Epsilogen, Genmab, GSK, Immunogen, Incyte, Leucid Bio, Lilly, MSD Pharma&, and Tubulis. NL received institutional research funding from Shattuck Labs for this study. He also reports institutional research funding from Adcentryx, Alexion, Alkermes, Alkermes\/Mural Oncology, Alpine, Alpine Biosciences, ALX Therapeutics, Apexian, Arcus Bio, Arcus Biosciences, Artios, Asana, Ascentage, Astellas, Aulos, Beigene, Biontech, Bristol Myers, Bristol Myers\/Celgene, Celgene, Cerulean, Constellation, CytomX, Day One Bio, Formation Biologics, forbius, Forty Seven, Gilead, GSK, Helsinn, Ikena, Incyte, InhibRx, Innovent Biologics, Jounce, KSQ Therapeutics\/Roche, Lilly, Livzon, Loxo\/Lilly, Macrogenics, Merck, Mersana, Northern Biologics, Odonate, other from Janssen, other from Revolution Medicines, Pfizer, Pharma\/Morphosys, Quanta Therapeutics, Regeneron, Repare Therapeutics, Samumed, Sapience, Seagen\/Pfizer, Servier Therapeutics, SK Life Sciences, Symphogen, Tizona and Circle Pharma, Volastra. SB received institutional research funding from Shattuck Labs for this study. She also reports institutional research funding from AstraZeneca and GSK, and honoraria for consulting or serving in an advisory role for AbbVie, AstraZeneca, Beigene, Biontech, Eisai, Epsilogen, Gilead, GlaxoSmithKline, Genmab, Grey Wolf Therapeutics, Immunogen, Incyte, ITM Oncologics, Lilly, Merck Sharpe Dohme, Mersana, Myriad, Oncxerna, Pharma&, Seagen, Takeda, TORL BioTherapeutics, Verastem, Zai Laboratories, Zymeworks. DM received institutional research funding from Shattuck Labs for this study. She also reports institutional research funding from Merck, PinotBio, Eisai, and Acrivon. She has consulted or served in an advisory role for CVS Health, Eisai, GSK. AMO (Amit Oza) received institutional research funding from Shattuck Labs for this study. He also reports institutional research funding from AbbVie, Amgen and AstraZeneca. He also reports honoraria for consulting or serving in an advisory role for AstraZeneca (Steering Committee), BMS- Oncology Tumor Advisory Council, GlaxoSmithKline (Steering Committee), Immunogen, Senhwa Biosciences, Sutro Biopharma, Verastem Oncology (Steering Committee). RM received institutional research funding from Shattuck Labs for this study. She also reported receiving honoraria for serving on advisory boards for AbbVie, AstraZeneca, Clovis Oncology, Eisai, Ellipses, GSK, MSD, and Pharma&. DY received institutional research funding from Shattuck for this study. MPBG received institutional research funding from Shattuck Labs for this study. She also reports honoraria from AbbVie, AstraZeneca, Eisai, Genmab, GSK, MSD, Pharma&, Regeneron for serving on advisory boards and for attending meetings. JMG received institutional research funding from Shattuck Labs for this study. He also reports honoraria for educational events from GSK, AstraZeneca, PHARMA and Novartis. GW is a former employee and stockholder of Shattuck Labs. JM is an employee and stockholder of Shattuck Labs. AF is an employee and stockholder of Shattuck Labs. EG is an employee of Pivotal CRO and was the contract medical monitor for the study. LP is an employee and stockholder of Shattuck Labs. DR reports institutional research funding from Shattuck Labs for this study. She also reports honoraria for consulting or for serving on advisory boards for Araris, AstraZeneca, Corcept, Daiichi Sankyo, Eisai, Genmab, Genelux, GSK, Incyclix bio, Mersana, and Repare Therapeutics. She reports institutional Research funding from A2A Pharmaceuticals, Aadi, AbbVie, Allorian, AstraZeneca, Blueprint medicines, Daiichi Sankyo, Duality Bio, Genmab, GSK, Immunogen, Karyopharm, Mersana, Nimbus therapeutics, Nurix therapeutics, Oncusp therapeutics, PMV pharmaceuticals, Syros, Totus, Tubulis, Xencor, and Zentalis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This trial was conducted in full conformity with the Declaration of Helsinki and was approved by all Institutional Review Boards\/ethics committees from each clinical site participating in the trial. All patients provided written informed consent in accordance with ICH\/GCP guidelines and applicable local regulations prior to trial initiation. Ethics approval: This study involves human participants. This study was conducted between 27-Sep 2022 and 31-Dec 2024, at 21 locations in Canada, United States, United Kingdom, and Spain in full conformity with the Declaration of Helsinki and was approved by all Institutional Review Boards\/ethics committees (IRB\/EC) from each clinical site participating in the study. All patients provided written informed consent in accordance with ICH\/GCP guidelines and applicable local regulations prior to study initiation. The following is a list of the IRB\/EC that approved the study: Advarra IRB (study number Pro00064445; University of Oklahoma and Northwestern University); Salus IRB (STMW2021.74; START Mid-West); WCG (study number 1336957; City of Hope); University of Arkansas IRB (study number 274809); University of British Columbia Ethics Board (study number H22-01821); McGill University Health Center Research Ethics Board (study number 2023-9103); University Health Network Research Ethics Board (study number 22-5652); COMIT\u00c9 DE \u00c9TICA DE LA INVESTIGACI\u00d3N CON MEDICAMENTOS Regional de la Comunidad de Madrid (study number 2022-000698-17; Instituto Catalan de Oncologia; Instituto Quiron Dexeus; START Fundacion Jimenez Diaz; Hospital Universitari Germans Trias I Pujol; Hospital Clinic de Barcelona; Hospital Vall d\u2019Hebron; Hospital Universitario Virgen de la Arrixaca), and South Central Oxford B Research Ethics Committee (study number 1006068; The Royal Marsden NHS Foundation Trust; Guy\u2019s & St. Thomas\u2019 NHS Foundation Trust; University College London Hospital NHS Foundation Trust; The Christie NHS Foundation Trust; The Royal Marsden NHS Foundation Trust).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}